Zacks
Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals
📈
AI Sentiment
Highly Positive
8/10
- Home
- KALV
as of 12-09-2025 3:45pm EST
$16.32
$0.54
-3.20%
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
Chart Type:
Time Range:
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | FRAMINGHAM |
| Market Cap: | 551.2M | IPO Year: | N/A |
| Target Price: | $26.43 | AVG Volume (30 days): | 1.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.95 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.30 - $17.28 | Next Earning Date: | 11-10-2025 |
| Revenue: | $1,426,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 204.16% |
AI-Powered KALV Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 73.47%
73.47%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of KalVista Pharmaceuticals Inc. (KALV)
Sweeny Nicole
Sell
Chief Commercial Officer
KALV Nov 24, 2025
Avg Cost/Share
$13.45
Shares
3,813
Total Value
$51,288.66
Owned After
39,728
SEC Form 4
Palleiko Benjamin L
Sell
CHIEF EXECUTIVE OFFICER
KALV Nov 18, 2025
Avg Cost/Share
$14.48
Shares
4,466
Total Value
$64,665.00
Owned After
403,879
SEC Form 4
Yea Christopher
Sell
CHIEF DEVELOPMENT OFFICER
KALV Nov 18, 2025
Avg Cost/Share
$14.48
Shares
2,683
Total Value
$38,848.23
Owned After
133,574
SEC Form 4
Audhya Paul K.
Sell
CHIEF MEDICAL OFFICER
KALV Nov 18, 2025
Avg Cost/Share
$14.48
Shares
3,075
Total Value
$44,524.46
Owned After
125,877
SEC Form 4
Palleiko Benjamin L
Sell
CHIEF EXECUTIVE OFFICER
KALV Nov 12, 2025
Avg Cost/Share
$11.55
Shares
3,328
Total Value
$38,438.40
Owned After
403,879
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Sweeny Nicole | KALV | Chief Commercial Officer | Nov 24, 2025 | Sell | $13.45 | 3,813 | $51,288.66 | 39,728 | |
| Palleiko Benjamin L | KALV | CHIEF EXECUTIVE OFFICER | Nov 18, 2025 | Sell | $14.48 | 4,466 | $64,665.00 | 403,879 | |
| Yea Christopher | KALV | CHIEF DEVELOPMENT OFFICER | Nov 18, 2025 | Sell | $14.48 | 2,683 | $38,848.23 | 133,574 | |
| Audhya Paul K. | KALV | CHIEF MEDICAL OFFICER | Nov 18, 2025 | Sell | $14.48 | 3,075 | $44,524.46 | 125,877 | |
| Palleiko Benjamin L | KALV | CHIEF EXECUTIVE OFFICER | Nov 12, 2025 | Sell | $11.55 | 3,328 | $38,438.40 | 403,879 |
Latest KalVista Pharmaceuticals Inc. News
KALV Breaking Stock News: Dive into KALV Ticker-Specific Updates for Smart Investing
Investor's Business Daily
Pharvaris Surges, Pulling KalVista Out Of A Slump, On Promising New HAE Treatment
📈
AI Sentiment
Highly Positive
8/10
Compare KALV vs Leading Stocks
See how KALV stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "KALV KalVista Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.